%0 Journal Article
%A Vaz-Salgado, Maria Angeles
%A Cigarral-Garcia, Belen
%A Fernandez-Perez, Isaura
%A Jimenez-Munarriz, Beatriz
%A Sampedro-Domarco, Paula
%A Hernandez-Gonzalez, Ainhoa
%A Vieito-Villar, Maria
%A Luque-Caro, Raquel
%A Villamayor-Delgado, Maria Luisa
%A Sepulveda-Sanchez, Juan Manuel
%T SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)
%D 2024
%@ 1699-3055
%U https://hdl.handle.net/10668/28621
%X The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.
%K Astrocytoma
%K Guideline
%K IDH mutation
%K Low-grade glioma
%K Neuro-oncology
%K Oligodendroglioma
%~